Actavis Receives FDA Approval for Viibryd (vilazodone HCl) 20mg Once Daily as a Therapeutic Dose

DUBLIN, March 16, 2015 /PRNewswire/ — Actavis plc (NYSE: ACT) today announced the U.S. Food and Drug Administration (FDA) has approved a lower therapeutic dose of Viibryd (vilazodone HCl) (20mg) to accompany the 40 mg daily therapeutic dose. This… – New Drug Approvals

Pharmaceutical Stocks


© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us